Randomized trial · people
Pramlintide: weight loss maintained over 12 months in obesity
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, adding pramlintide to a lifestyle program helped people with obesity lose more weight than placebo and keep it off for a year at two of the dosing schedules, with nausea as the main early side effect.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 411
- Published
- 2008
- Journal
- Diabetes Care
What they tested
The team tested how well different pramlintide dosing schedules, added to a lifestyle program, produced and kept off weight loss over 12 months, and how safe they were.
How the study was done
A 4-month double-blind, placebo-controlled trial (placebo, a dummy treatment) randomly assigned 411 people with obesity to placebo or one of six pramlintide arms (120, 240 or 360 microg, given twice or three times a day), all alongside a structured weight-loss lifestyle program. People who could be evaluated at month 4 could continue their assigned treatment in an 8-month single-blind extension focused on keeping weight off, and 77% of them chose to.

Model. Individual results vary.
What they found
At month 4, average weight loss in the pramlintide arms ranged from 3.8 to 6.1 kg, compared with 2.8 kg on placebo. By month 12, the placebo group had regained the weight it lost early on, while every pramlintide arm except 120 microg twice daily held its loss. Compared with placebo, the 120 microg three-times-daily and 360 microg twice-daily arms lost 6.1 kg (5.6% of body weight) and 7.2 kg (6.8% of body weight) more at month 12, and 40% and 43% of those groups lost at least 10% of their weight, versus 12% on placebo. Nausea was the most common side effect in the first 4 months (9-29% on pramlintide vs. 2% on placebo), was mostly mild to moderate, and affected under 10% of people during the extension.
What it doesn’t show
Only 146 people could be evaluated at month 12, and the extension was single-blind and open to those who chose to continue, so the 12-month results come from a smaller, self-selected group. Every participant also followed a structured lifestyle program, so the results apply to pramlintide used together with one.
The paper
Smith et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008.
The compound
More studies on Pramlintide
- Pramlintide: HbA1c down 0.43% vs placebo at 26 weeks with insulinMeta-analysis · people · 2003
- Pramlintide-insulin loop: time in range held without carb countingRandomized trial · people · 2025
- Pramlintide-insulin mix: 2.1 kg more weight loss than lisproRandomized trial · people · 2024
- Pramlintide/insulin ADO09 cut meal glucose rise 69% in high-dose groupRandomized trial · people · 2023
- Pramlintide: 3.7% placebo-corrected weight loss at 16 weeksRandomized trial · people · 2007
- Pramlintide lowered post-meal glucagon and glucose in type 2 diabetesRandomized trial · people · 2002
- Every study on Pramlintide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.